Core Viewpoint - ST Tian Sheng (002872.SZ) announced that its wholly-owned subsidiaries, Hubei Tian Sheng Pharmaceutical Co., Ltd. and Hunan Tian Sheng Pharmaceutical Co., Ltd., participated in the procurement of drugs including Dexamethasone in Guangdong Province, with several products proposed for selection in the upcoming procurement process [1] Group 1: Company Participation - Hubei Tian Sheng and Hunan Tian Sheng participated in the Guangdong Alliance procurement for Dexamethasone and other drugs [1] - The Guangdong Provincial Drug Trading Center published the proposed selection results for the procurement on October 10, 2025 [1] Group 2: Selected Products - Hubei Tian Sheng's products proposed for selection include: - Concentrated Sodium Chloride Injection - Clindamycin Hydrochloride Injection - Glucose Injection - Sodium Chloride Injection [1] - Hunan Tian Sheng's products proposed for selection include: - Cefoperazone Injection - Cefazolin Sodium Injection [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 永發置業有限公司 | | | 呈交日期: | 2025年10月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00287 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 40,000,000 | | 0 | | 40,000,000 | | 增加 / 減少 (-) | | | | | | | | ...

Core Viewpoint - ST Tian Sheng has been penalized for financial fraud involving off-balance sheet funds, resulting in a total fine of 4.39 million yuan for the company and 22 responsible individuals [3][4]. Financial Fraud Details - The financial fraud methods employed by ST Tian Sheng primarily revolved around an "off-balance sheet fund pool," where the company inflated project costs and procurement expenses to siphon funds into a hidden pool [4]. - In the annual reports for 2017 and 2018, ST Tian Sheng inflated total profits by 175 million yuan and 47.9 million yuan, respectively, while also reducing profits by 82.58 million yuan and 19.09 million yuan through inflated procurement costs [4]. - The total inflated profits for 2017 and 2018 amounted to 92.20 million yuan and 28.82 million yuan, representing 30.21% and 20.61% of the reported profits for those years [4]. Undisclosed Related Transactions - The undisclosed related transactions for 2017 and 2018 reached 481 million yuan and 48.63 million yuan, accounting for 15.08% and 1.49% of the net assets at the end of those periods [5]. - Notably, after the company's listing, the undisclosed related transactions amounted to 329 million yuan, exceeding 15% of the most recent audited net assets [5]. Regulatory Actions - The Chongqing Securities Regulatory Bureau imposed penalties on ST Tian Sheng for failing to disclose related transactions and for false reporting in the 2017 and 2018 annual reports, including a warning and a fine of 600,000 yuan [6]. - Key individuals, including Liu Qun, received significant fines and market bans, with Liu Qun facing a total fine of 900,000 yuan and a lifetime ban from the securities market [6]. Legal Consequences for Executives - Liu Qun, the actual controller of ST Tian Sheng, was sentenced to 19 years in prison for multiple crimes, including bribery and embezzlement, along with fines totaling 2 million yuan and the confiscation of personal assets worth 8 million yuan [7]. Internal Governance Issues - The financial fraud case highlights severe deficiencies in the company's internal governance, leading to a risk warning status since April 2019, with the stock name changed to "ST Tian Sheng" [8]. - The company's recent performance has been poor, with a reported revenue of 232 million yuan in the first half of 2025, a year-on-year decline of 17.49%, and a net loss of 36.71 million yuan [8].

人民财讯9月18日电，截至午间收盘，恒生指数跌0.18%，恒生科技指数涨1.04%。港股芯片股走强，华 虹半导体、晶门半导体涨超10%，中芯国际涨超6%。 ...

Core Viewpoint - ST Tian Sheng (002872.SZ) announced that its wholly-owned subsidiary, Hubei Tian Sheng Pharmaceutical Co., Ltd., has received the approval notice from the National Medical Products Administration for its product "Sodium Bicarbonate Injection," which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval of "Sodium Bicarbonate Injection" indicates a significant milestone for the company in the pharmaceutical sector [1] - The consistency evaluation is crucial for generic drugs, ensuring they meet the same quality and efficacy standards as their branded counterparts [1]

Group 1 - The company ST Tian Sheng (002872.SZ) received an administrative penalty notice from the China Securities Regulatory Commission on September 12, 2025, indicating that the financial indicators in its annual report contained false records [1] - The notice states that the company violated Article 9.8.1, Item 8 of the Shenzhen Stock Exchange Listing Rules, which will result in additional risk warnings for its stock [1] - Following the additional risk warning, the stock will continue to be traded under the name "ST Tian Sheng" with the same stock code 002872, and the daily price fluctuation limit remains at 5% [1]

Group 1 - The stock of ST Tian Sheng (002872) closed at 4.78 yuan on September 11, 2025, down 0.21%, with a turnover rate of 1.21% and a trading volume of 26,000 hands, amounting to a transaction value of 12.34 million yuan [1] - On September 11, the net outflow of main funds was 985,600 yuan, while retail investors saw a net inflow of 447,900 yuan [3] - The controlling shareholder Liu Qun was involved in the misappropriation of company funds, with a total of approximately 125 million yuan being misappropriated and later repaid by Liu Qun by April 8, 2021 [1][3] Group 2 - The Chongqing First Intermediate People's Court made a criminal judgment on December 29, 2023, confirming the misappropriation of funds, and Liu Qun has returned the funds [1] - The Chongqing High People's Court upheld the original judgment on August 8, 2024, rejecting Liu Qun's appeal [1] - Beijing Xinghua Accounting Firm issued a qualified opinion on the company's 2024 financial report due to an ongoing investigation by the CSRC regarding information disclosure violations related to the company and Liu Qun [1]

Core Viewpoint - ST Tian Sheng (002872) has been under other risk warnings since June 5, 2019, due to the alleged misappropriation of company funds by its controlling shareholder Liu Qun, who has been ordered to repay a total of 125,074,926 yuan [1] Group 1: Stock Performance - As of September 10, 2025, ST Tian Sheng closed at 4.79 yuan, up 0.42% from the previous trading day, with a total market capitalization of 1.523 billion yuan [1] - The stock opened at 4.75 yuan, reached a high of 4.81 yuan, and a low of 4.74 yuan, with a trading volume of 839.29 thousand yuan and a turnover rate of 0.82% [1] Group 2: Legal and Financial Developments - Liu Qun was sentenced to repay 91.824926 million yuan for misappropriated funds and 33.25 million yuan for misused funds, totaling 125,074,926 yuan [1] - As of April 8, 2021, all principal and interest of the funds occupied by Liu Qun had been fully repaid [1] - On December 29, 2023, the Chongqing First Intermediate People's Court confirmed the misappropriation and misused funds, and Liu Qun has returned the funds [1] - The Chongqing High People's Court upheld the original ruling on August 8, 2024, dismissing Liu Qun's appeal [1] - Beijing Xinghua Accounting Firm issued a qualified opinion on the company's 2024 financial report due to an ongoing investigation by the CSRC regarding information disclosure violations [1] - The company is cooperating with the investigation while maintaining normal production and operations [1]

2025 年 股 東 週 年 大會 投 票 表 決 結果 永發置業有限公司(「本公司」)之董事會欣然公布，於二零二五年九月三日舉行 之股東週年大會(「該週年大會」)上進行之投票結果。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公 告 的內容概不 負 責 ， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明 ， 並 明 確 表 示 ， 概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任 。 (1) 股 東有權 出席並 可在該 週年大 會上就 所有決 議案投 贊成票 或反對 票之股 份 總數為：40,000,000 股。 (2) 股東有權出席但只可在該週年大會上就若干決議案投反對票之股份總數：無。 (3) 本公司股東於該週年大會上就提呈之決議案進行表決時，未受任何限制。 (4) 在 該週年 大會上 就各項 決議案 投贊成 票或反 對票之 所有代 表的股 份數目 如 下： | 4. | 續聘香港立信德豪會計師事務所有限公司為本 公司核數師並授權董事會釐定其酬金。 | 17,129,128 (99.999982%) | 3 (0.000018 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 永發置業有限公司 | | | 呈交日期: | 2025年9月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00287 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 40,000,000 | | 0 | | 40,000,000 | | 增加 / 減少 (-) | | | | | | | | | ...